The utilization of leukocytes as carriers to improvethe accumulationof nanomedicine at the tumor site has garnered increasing attention.In a recent study, Qi et al. developed a nanomedicine (ES-DSM) byencapsulating DOX and SCH58261 (an A2AR antagonist) in E-selectin-modifiedthermal-sensitive micelles (Figure 13D, Table 5).189 Due to the presence of E-selectin,ES-DSMs specifically adhered to the surface of leukocytes and subsequentlyrode leukocytes across biological barriers, thus improving their tumoraccumulation. The gene discussed is ADORA2A; the disease is neoplasm.